Evidence map›Paper›PMID 25646359›Full record

ArticleJournal of leukocyte biology2015

SAMHD1's protein expression profile in humans.

Sarah Schmidt, Kristina Schenkova, Tarek Adam, Elina Erikson, Judith Lehmann-Koch, Serkan Sertel, Bruno Verhasselt, Oliver T Fackler, Felix Lasitschka, Oliver T Keppler

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of leukocyte biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Characterization of a mutantFrontiers in immunology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Sarah Schmidt*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Kristina Schenkova*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Tarek Adam*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Elina Erikson*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Judith Lehmann-Koch*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Serkan Sertel*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Bruno Verhasselt*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Oliver T Fackler*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Felix Lasitschka*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium.
Oliver T Keppler*Institute of Medical Virology, National Reference Center for Retroviruses, University of Frankfurt, Germany; Department of Infectious Diseases, Integrative Virology, Institute of Pathology, and Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Germany; German Centre for Infection Research, Heidelberg, Germany; and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium oliver.keppler@kgu.de.
German Center for Infection Research · DEHeidelberg University · DEInstitute of Medical Microbiology and Hygiene · DEGhent University · BEGoethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The deoxynucleoside triphosphate triphosphohydrolase and 3' → 5' exonuclease SAMHD1 restricts HIV-1 infection in noncycling hematopoietic cells in vitro, and SAMHD1 mutations are associated with AGS. Little is known about the in vivo expression and functional regulation of this cellular factor. Here, we first assessed the SAMHD1 protein expression profile on a microarray of 25 human tissues from >210 donors and in purified primary cell populations. In vivo, SAMHD1 was expressed in the majority of nucleated cells of hematopoietic origin, including tissue-resident macrophages, DCs, pDCs, all developmental stages of thymic T cells, monocytes, NK cells, as well as at lower levels in B cells. Of note, SAMHD1 was abundantly expressed in HIV target cells residing in the anogenital mucosa, providing a basis for its evaluation as a cellular factor that may impact the efficiency of HIV transmission. Next, we examined the effect of the activation status and proinflammatory cytokine treatment of cells on expression and phosphorylation of SAMHD1. Activated, HIV-susceptible CD4(+) T cells carried pSAMHD1(T592), whereas resting CD4(+) T cells and macrophages expressed the unphosphorylated protein with HIV-restrictive activity. Surprisingly, stimulation of these primary cells with IFN-α, IFN-γ, IL-4, IL-6, IL-12, IL-18, IL-27, or TNF-α affected neither SAMHD1 expression levels nor threonine 592 phosphorylation. Only IL-1β moderately down-regulated SAMHD1 in activated CD4(+) T cells. Taken together, this study establishes the first cross-sectional protein expression profile of SAMHD1 in human tissues and provides insight into its cell cycle-dependent phosphorylation and unresponsiveness to multiple proinflammatory cytokines.

Indexed as

Gene Expression ProfilingCell LineCytokinesHIV-1HumansLymphocyte ActivationMembrane FusionMonomeric GTP-Binding ProteinsPhosphorylationSAM Domain and HD Domain-Containing Protein 1T-LymphocytesCytokinesMonomeric GTP-Binding ProteinsSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, humanHIVHSVinnate immunityrestriction factor

Identifiers

PMID25646359
PMCPMC7166976
OpenAlexW2133608634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.